# US 2024/0254470 A1 · Protein producer cells made by fusing cells together and selecting for high level expression of a transgene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254470 A1
- Document ID: US20240254470A1
- Status: Published application
- Kind: A1
- Application number: 18/634,846
- Filed: 2024-04-12
- Published: 2024-08-01
- Earliest claimed: 2015-09-03
- Assignees: CHO Plus, Inc.
- Applicants: CHO Plus, Inc.
- Inventors: Lawrence Forman
- Web page: https://patentgrep.com/patent/US20240254470A1

## CPC

- C12N 15/02: Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies C07K16/00; apparatus for cell fusion C12M)}
- C12N 5/0682: {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N5/0609)}
- C12N 5/16: Animal cells
- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- C12N 2511/00: Cells for large scale production
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure provides improved cell lines for manufacturing a target protein, thereby reducing the cost of commercial production. Cell hybrids are formed by fusing together cells from a starting cell population. An expressible transgene is introduced into the cells before or after the fusing. A product of the transgene can then by used to select and recover cell hybrids that are capable of producing protein at a higher level than other cell hybrids or the starting cell population. The selected cells are cloned and expanded to establish a producer cell line. The target protein may be a pharmaceutical agent such as an antibody or a hormone, or a food ingredient such as a heme binding protein. Engineered cell lines can be obtained that produce 8-fold more protein per cell than the starting cell line.

## Claims

### Claim 1

A method of preparing a producer cell line comprising:
(a) forming cell hybrids by fusing together cells from a starting cell population, wherein each hybrid comprises two or more cells from the starting cell population;
(b) genetically altering cells in the starting cell population or the cell hybrids with a transgene encoding a protein; and
(c) selecting and recovering cell hybrids that express the protein at a higher level compared with cells from the starting population and other cell hybrids;
thereby obtaining a producer cell line that supports increased production and/or secretion of said protein compared with other cells in the starting cell population.

### Claim 2 (depends on 1)

The method of claim 1, wherein the protein is optically detectable, and step (c) comprises using a cell sorter to select the cells that express the protein at the higher level.

### Claim 3 (depends on 1)

The method of claim 1, wherein the protein is not optically detectable, and step (c) comprises dividing the cells from step (b) into a plurality of aliquots, then sampling and testing each aliquot to select aliquots containing cells that express the protein at the higher level.

### Claim 4 (depends on 3)

The method of claim 3, wherein said aliquots are clones of the genetically altered cells from step (b).

### Claim 5 (depends on 1)

The method of claim 1, wherein said protein is a protein intended for commercial production.

### Claim 6 (depends on 1)

The method of claim 1, wherein said protein is a pharmaceutical agent.

### Claim 7 (depends on 1)

The method of claim 1, wherein said protein is a target protein selected from an antibody chain, a therapeutic enzyme, a hormone, a growth factor, and a naturally occurring component of blood.

### Claim 8 (depends on 1)

The method of claim 1, wherein said protein is an antibody molecule.

### Claim 9 (depends on 1)

The method of claim 1, wherein said protein is a food ingredient.

### Claim 10 (depends on 9)

The method of claim 9, wherein said protein is a heme binding protein.

### Claim 11 (depends on 9)

The method of claim 9, wherein said protein is a leghemoglobin or a myoglobin.

### Claim 12 (depends on 1)

The method of claim 1, wherein said protein is an optically detectable reporter protein, or wherein said protein is an enzyme that catalyzes formation of an optically detectable product from a substrate.

### Claim 13 (depends on 12)

The method of claim 12, wherein said protein is luciferase, green fluorescent protein (GFP), or secreted alkaline phosphatase (SEAP).

### Claim 14 (depends on 12)

The method of claim 12, wherein said protein is a fusion protein containing a fluorescent or bioluminescent peptide that generates an optical signal fused with a peptide that is processed by endoplasmic reticulum.

### Claim 15 (depends on 1)

The method of claim 1, further comprising genetically altering the cells selected and recovered in step (c) to express a protein intended for commercial production.

### Claim 16 (depends on 12)

The method of claim 12, further comprising substituting the transgene used for the selecting in step (c) with a different transgene encoding a protein intended for commercial production.

### Claim 17 (depends on 1)

The method of claim 1, wherein the cell hybrids are formed from a single cell line.

### Claim 18 (depends on 16)

The method of claim 16, wherein the cell line is a line of CHO cells or a line of HEK293 cells.

### Claim 19 (depends on 1)

The method of claim 1, further comprising selecting and recovering cell hybrids that have a relatively high density of endoplasmic reticulum per cell, compared with other hybrids.

### Claim 20 (depends on 1)

The method of claim 1, further comprising selecting and recovering cell hybrids that have a relatively high density of Golgi apparatus per cell, compared with other hybrids.

### Claim 21 (depends on 1)

The method of claim 1, wherein cells from the producer cell line obtained thereby produce at least 50 to 200 pg/cell/day of said protein.

### Claim 22 (depends on 1)

The method of claim 1, wherein cells from the producer cell line obtained thereby produce at least eight grams of said protein per liter of media in which they are cultured.

### Claim 23 (depends on 6)

A method of producing a pharmaceutical composition, comprising culturing cells from the producer cell line according to claim 6 so that the cells express the pharmaceutical agent, purifying the pharmaceutical agent from the cell culture, and compounding the pharmaceutical agent in a manner suitable for human administration.

### Claim 24 (depends on 9)

A method of producing a meat replacement product, comprising culturing cells from the producer cell line according to claim 9 to express the heme binding protein, purifying the heme binding protein from the cell culture, and manufacturing a processed food containing the heme binding protein.
